|
SB-649,868 is a dual orexin receptor antagonist in development by GlaxoSmithKline. The drug is currently in phase II development for insomnia. A phase I study evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse effects. In randomized, double-blind, placebo-controlled crossover trials, the 10 and 30 mg doses increased sleep time and reduced sleep latency. The subsequent study added a 60 mg dose and observed dose-dependent sleep promotion. ==See also== * Almorexant * Filorexant * Lemborexant * Suvorexant 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「SB-649,868」の詳細全文を読む スポンサード リンク
|